Mackenzie Bean / beckershospitalreview - GLP-1 receptor agonists carry a higher risk of hair loss than other diabetes medications, according to a study published July 22 in The BMJ. Researchers at Philadelphia-based Penn Medicine used EHR data to compare adults with Type 2 diabetes who started G…
AI Summary: A series of new analyses tie GLP‑1 diabetes and obesity drugs to a measurable rise in hair loss reports, with varying risk estimates prompting doctors to warn patients and researchers to dig deeper. Clinicians urge monitoring and clearer guidance as these widely used medications shift from metabolic miracles to potential cosmetic headaches.
GLP‑1 drugs associated with lower addiction risk in large study / 4 months
Compounding Pharmacy Sues Lilly and Novo Nordisk / 6 months
FDA Removes Suicide Warnings from GLP‑1 Drugs / 6 months
Lilly’s Zepbound bests Novo’s CagriSema in head‑to‑head obesity trial / 4 months
Trump Administration Secures Lower Obesity Drug Prices / 8 months
Apitegromab preserves muscle while patients lose weight on GLP‑1s / 6 wks
Amazon expands access to Ozempic pill with delivery and kiosks / 2 months
StackHealth RSS


StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.